ArticleFrontiers in immunology2026
Investigating the role of the TGF-β-SLC20A1 axis in the spatial heterogeneity of hepatocellular carcinoma through single-cell and spatial transcriptomics.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neuroimmune regulation of post-traumatic bone regeneration: focus on inflammatory switching and functional recovery.Frontiers in immunology · 2026Review
- Mechanisms and therapeutic strategies of bidirectional crosstalk between hepatic stellate cell-derived cancer-associated fibroblasts and T cells in immune evasion and therapeutic resistance of hepatocellular carcinoma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is a highly heterogeneous malignancy characterized by marked cellular and spatial diversity within the tumor microenvironment (TME). The transforming growth factor-β (TGF-β) signaling pathway plays a dual role in the initiation and progression of HCC. However, the spatial distribution characteristics and key regulatory mechanisms of TGF-β signaling within HCC tissues remain inadequately elucidated. Methods: This study integrated spatial transcriptomics (ST), single-cell RNA sequencing (scRNA-seq), and bulk RNA-seq data to systematically characterize the spatial heterogeneity of the TGF-β signaling pathway in HCC. By combining non-negative matrix factorization (NMF), CellChat-based cell-cell communication analysis, and multi-algorithm machine learning approaches, we identified key driver genes closely associated with TGF-β activity. Subsequently, CCK-8 assays, colony formation, wound-healing, and Western blot experiments were performed in HCC cell lines to validate the biological functions of the identified gene. Results: The results revealed that the TGF-β signaling pathway exhibited the highest activity at the tumor-stroma interface, which was enriched with cancer-associated fibroblasts (CAFs), immunosuppressive cells, and genes related to extracellular matrix (ECM) remodeling. CellChat analysis showed that TGF-β-TGFBR ligand-receptor interactions between tumor cells, CAFs, and immune cells were markedly enhanced, contributing to the formation of a localized immunosuppressive microenvironment. Machine learning analysis identified SLC20A1 as a key regulatory factor. Functional assays demonstrated that SLC20A1 enhances the proliferation, migration, and epithelial-mesenchymal transition (EMT) of HCC cells, whereas its knockout significantly suppresses these malignant phenotypes. Conclusion: This study represents the first comprehensive integration of spatial and single-cell transcriptomics to uncover the spatial organization of TGF-β signaling in HCC and to identify the TGF-β-SLC20A1 axis as a critical driver of tumor invasion at the tumor-stroma interface. Our findings provide new mechanistic insights into tumor-stroma interactions and suggest a potential therapeutic target for precision treatment of HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.